Funding round
Baseimmune Series A
Baseimmune, which works in active immunotherapy development in London, raised $11M in a Series A round announced on 26 Feb 2024, led by MSD Global Health Innovation Fund and IQ Capital. 11 firms took part. It is Baseimmune's second venture round on record; the one before was a Seed in Apr 2021.
$11M
Amount raised
Not disclosed
Post-money valuation
11
Investors
2 leads
Valuation
What this round says about the price
Baseimmune did not disclose a valuation in this round. It came 34 months after Baseimmune's Seed. It is 92% of the $12M Baseimmune has raised in the venture rounds on record. No later venture round is on record for Baseimmune.
Baseimmune's funding rounds
Baseimmune has 2 venture rounds on record and 1 other deal. This one is highlighted.
- Seed 1 Apr 2021, led by The Creator Fund $945K
- Other not a venture round 2 Nov 2021, led by Hoxton Ventures $4.8M
- Series A this round 26 Feb 2024, led by MSD Global Health Innovation Fund and IQ Capital $11M
Investors
Who put money in
MSD Global Health Innovation Fund and IQ Capital led the round with 9 other firms.
Lead investors
- MSD Global Health Innovation Fund new investor
- backs 51 venture-backed companies new investor
Also in the round
- Hoxton Ventures backs 50 venture-backed companies new investor
- backs 19 venture-backed companies new investor
- backs 4 venture-backed companies new investor
- backs 32 venture-backed companies new investor
- AME Cloud Ventures backs 105 venture-backed companies new investor
- Founders Fund backs 368 venture-backed companies new investor
- backs 43 venture-backed companies new investor
- LAUNCHub backs 36 venture-backed companies new investor
- backs 25 venture-backed companies new investor
Use of proceeds
What the money is for
According to the announcement, the money goes to product development, scaling operations and working capital.
- Product development
- Scaling operations
- Working capital
Comparable rounds
How it compares
175 Series A rounds in Biotechnology within a year either side disclosed an amount; the median was $30M, and this round was 38% of the median. The closest in time, other companies' Series A rounds in Biotechnology:
| Company | Announced | Amount | Post-money | Led by |
|---|---|---|---|---|
| Biotechnology | 15 Feb 2024 | $94M | not disclosed | Versant Ventures and MPM BioImpact |
| Biotechnology | 29 Feb 2024 | $82M | not disclosed | Alaska Permanent Fund Corporation and Cure Ventures |
| Biotechnology | 27 Feb 2024 | $51M | not disclosed | Pfizer Ventures and Epidarex |
| Biotechnology | 1 Feb 2024 | $13M | not disclosed | CDIB Capital |
| Biotechnology | 17 Feb 2024 | $8.1M | not disclosed | Corteva Agriscience |
| Mirador Biotechnology | 21 Mar 2024 | $400M | not disclosed | ARCH Venture Partners |
| Biotechnology | 26 Mar 2024 | $150M | not disclosed | New Enterprise Associates and Deep Track Capital |
| Biotechnology | 20 Mar 2024 | $150M | not disclosed | Catalio Capital Management and Third Rock Ventures |
Sources
Where this comes from
Reported by 3 sources.
Questions
Frequently asked
How much did Baseimmune raise in its Series A round?
Baseimmune raised $11M in its Series A round, announced in Feb 2024.
Who led Baseimmune's Series A round?
MSD Global Health Innovation Fund and IQ Capital led it, with Hoxton Ventures, The Creator Fund, BEAST, Maki.vc and AME Cloud Ventures and 4 more.
What was Baseimmune's valuation at the Series A round?
It was not disclosed.
How does it compare with other Series A rounds in Biotechnology?
175 Series A rounds in Biotechnology within a year either side disclosed an amount; the median was $30M, and this round was 38% of the median.